Aarti Drugs Peer Comparison

Snapshot Summary

Aarti Drugs Ltd. shows a mixed performance in comparison to its peers in the Pharmaceuticals & Drugs sector. While it exhibits lower revenue growth and profitability metrics compared to several competitors, its debt levels are manageable, suggesting a stable positioning. Companies like Cipla and Dr. Reddy's lead in profitability, while Aarti presents a value opportunity with its relatively lower valuation metrics.

• Aarti Drugs has a manageable debt-equity ratio of 0.4389, indicating lower financial risk.
• Its revenue growth has been negative YoY at -5.6%, suggesting current operational challenges.
• Cipla Ltd. and Dr. Reddy's Laboratories Ltd. exhibit significantly higher profitability with ROE above 16% and PE ratios suggesting overvaluation in the market.

• Cipla Ltd.: Highest profitability with significant revenue growth and low PE ratio.
• Dr. Reddy's Laboratories Ltd.: Strong profitability metrics with a low PE ratio and high return on equity.
• Mankind Pharma Ltd.: Impressive revenue growth and strong margins, although relatively higher PE.

Stock	CMP	Market Cap	P/E	ROE (%)	ROCE (%)	Debt/Equity
AARTIDRUGS	₹503.45	₹4,588.60Cr	24.30	12.68%	13.11%	0.45
SUNPHARMA	₹1,706.40	₹4,09,626.46Cr	39.49	16.16%	19.89%	0.03
DIVISLAB	₹6,804.00	₹1,80,668.62Cr	78.35	15.35%	20.45%	0.00
CIPLA	₹1,511.50	₹1,22,102.70Cr	22.44	16.63%	22.77%	0.01
TORNTPHARM	₹3,628.30	₹1,20,456.12Cr	60.17	26.46%	27.32%	0.40
DRREDDY	₹1,196.00	₹99,965.86Cr	17.32	18.61%	23.25%	0.14
ZYDUSLIFE	₹981.05	₹98,057.50Cr	21.45	21.08%	26.06%	0.13

Explore

Watchlists

Command Palette

Aarti Drugs Peer Comparison

Snapshot Summary